
Opinion|Videos|May 1, 2025
Genomic Assays in Breast Cancer: Key Differences, Clinical Utility, and Test Selection
Panelists discuss how they primarily use the 21-gene assay (Oncotype DX) for estrogen receptor–positive (ER+), HER2-negative (HER2–) breast cancers with minimal nodal disease due to its robust data from multiple trials, whereas other assays such as the Breast Cancer Index (BCI) are better for evaluating extended endocrine therapy benefits.
Advertisement
Comparing Available Genomic Assays
Main Discussion Topics:
- Differentiating factors between various genomic assays (Oncotype DX, MammaPrint, EndoPredict, Prosigna Breast Cancer Assay, BCI)
- Considerations for selecting the appropriate test for ER+/HER2– breast cancer
- Specific clinical scenarios where different assays may be preferred
Key Points for Physicians:
- The 21-gene assay (Oncotype DX) is preferred for ER+/HER2– breast cancers with negative or minimal nodal involvement due to robust supporting clinical trial data.
- BCI is valuable for assessing extended endocrine therapy benefit.
- The 70-gene assay (MammaPrint) may be useful for specific clinical trials and some HER2+ cases.
Notable Insights:
- Oncotype DX is supported by extensive clinical data (>80 trials/registries involving ~100,000 patients) and has been incorporated into staging systems.
- Test selection should be driven by the specific clinical question being addressed.
Clinical Significance: Although the 21-gene assay remains the most widely validated option for ER+/HER2– breast cancer, physicians should consider the specific clinical context and question when selecting between available genomic testing options.
Advertisement
Related to this article

The FDA has approved neladalkib for previously treated, ALK-positive, locally adanced or metastatic non-small cell lung cancer.

Roswell Park researchers found CD83 CAR T cells could overcome CD19-targeted therapy resistance in preclinical models of B-cell cancers.

Ryan J. Sullivan, MD, discusses HLA testing, liver-directed therapy, and emerging targeted and T-cell–based therapies for metastatic uveal melanoma.

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
4
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
5

